NCT00776425View on ClinicalTrials.gov

A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Anemia
Interventions
DRUG

Epoetin beta

Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.

Trial Locations (22)

105203

Moscow

125101

Moscow

150062

Yaroslavl

153040

Ivanovo

156005

Kostroma

163061

Arkhangelsk

170008

Tver'

185019

Petrozavodsk

191024

Saint Petersburg

197022

Saint Petersburg

197758

Saint Petersburg

354057

Sashi

390039

Ryazan

398005

Lipetsk

420111

Kazan'

450005

Ufa

625023

Tyumen

628408

Surgut

629001

Salekhard

630091

Novosibirsk

656049

Barnaul

ND

Belgorod

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00776425 - A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies | Biotech Hunter | Biotech Hunter